Exome-Based Rare-Variant Analyses in CKD
Sophia Cameron‐Christie(AstraZeneca (United Kingdom)), Ali G. Gharavi(Columbia University), Emily Groopman(West Coast University), Maddalena Marasà(Azienda Ospedaliero-Universitaria delle Marche), David B. Goldstein(Electronic BioSciences (United States)), Sahar Gelfman(Regeneron (United States)), Andrew S. Allen(Duke University), Simone Sanna‐Cherchi(Columbia University Irving Medical Center), Carolina Haefliger(AstraZeneca (United Kingdom)), Krzysztof Kiryluk(Columbia University), Charles J. Wolock, Dimitrios Vitsios(AstraZeneca (United Kingdom)), Ruth March(AstraZeneca (United Kingdom)), Adam Platt(AstraZeneca (United Kingdom)), Gundula Povysil(Bridgepoint (United States)), Mengqi Zhang(Ningbo University), Yifu Li(Harbin Medical University), Slavé Petrovski(AstraZeneca (United Kingdom)), Sitharthan Kamalakaran(Columbia University Irving Medical Center), Bengt Fellström(Uppsala University Hospital), Jan Fleckner(AstraZeneca (United Kingdom))
Cited by 58
Related Papers
Finding the missing heritability of complex diseases
|Nature|2009|8.5k
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
|Nature Reviews Genetics|2008|3k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k